# Role of breast cancer secreted miRNA in brain metastasis

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2022 · $436,985

## Abstract

PROJECT SUMMARY/ABSTRACT
Breast cancer metastasis to the brain is rising in prevalence and is an increasingly lethal threat to patients due
to the very limited treatment options and high mortality. Therefore, there is a great and urgent need to develop
novel preventive and therapeutic treatments for brain-homing metastatic cancer. Altered function of normal
cells in a metastatic niche has been recognized as an important means for cancer to facilitate metastasis. The
metabolic reprogramming of normal niche cells during cancer metastasis, however, remains largely
unexplored. The proposed project will investigate this unique aspect of cancer–host crosstalk from the novel
perspective of extracellular miRNA, whose function in transferring cancer-derived signals to various types of
niche cells to facilitate cancer growth and metastasis has been recently recognized. MiRNA negatively
regulates gene expression through inducing mRNA degradation and/or translation blockade. The goals of this
study are to identify the mechanism by which cancer cell-secreted miRNA reprograms the energy
metabolism of brain cells (neurons and astrocytes) to promote metastasis, to assess potential
therapeutic strategies to protect the brain using experimental models, and to evaluate the potential of
such miRNA as a novel blood-based biomarker for breast cancer brain metastasis. In Aim 1, we will
determine the effects and acting mechanism of selected breast cancer-secreted miRNA in the metabolic
reprogramming of brain cells and tissues, including a mechanism through suppression of nutrient influxes.
Mouse models will be used to elucidate how altered energy metabolism in the brain contributes to the stepwise
process of breast-to-brain metastasis. In Aim 2, we will assess the beneficial effects of experimental
therapeutics targeting cancer-induced adaptation of the brain as novel strategies to prevent or treat breast
cancer brain metastasis. In Aim 3, we will evaluate the potential of circulating miRNA as a clinical biomarker for
the prediction or early diagnosis of brain metastasis in breast cancer patients. We will also investigate
specimens of resected brain metastases for clinical evidence of the herein identified molecular mechanism.
The proposed project will provide a novel perspective to our understandings of the dynamic communication
between cancer and host and of the complex mechanisms underlying the development of brain metastases. It
may establish rationales for novel therapeutic strategies to prevent or treat brain-metastasizing cancer and
alleviate cancer’s adverse effects on brain function, which is our long-term objective. Importantly, our study
may establish circulating miRNA as a non-invasive biomarker to identify patients with a high risk of developing
brain metastases, thereby enabling a shift of our therapeutic focus to targeting the prevention of brain
metastases.

## Key facts

- **NIH application ID:** 10342786
- **Project number:** 1R01CA266486-01
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** Shizhen Emily Wang
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $436,985
- **Award type:** 1
- **Project period:** 2022-03-04 → 2027-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10342786

## Citation

> US National Institutes of Health, RePORTER application 10342786, Role of breast cancer secreted miRNA in brain metastasis (1R01CA266486-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10342786. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*